Source: Neuralstem.I haven’t bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap companies that come with risks that are common in this highly speculative pop-and-drop industry, but for investors willing to take a risk, these […]
See original:
Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead – Stocks in the News
[…]
If you put money in stocks at just about any point in the past six years, you’re probably pretty happy.America is in the midst of the fourth longest stock market expansion in history.Monday marks the six-year anniversary of the day the S&P 500 hit its low point after the financial crisis. Since then, the index has risen over 200%.But that […]
Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Source: Flickr user Ali T.Clinical stage biotech stocks can have nausea-inspiring pops-and-drops tied to news, and that makes them suitable for only the most risk-tolerant of investors. However, investors willing to accept the risk of loss can reap substantial rewards if promising pipeline drugs like Xoma Corp ‘s gevokizumab succeed in clinical trials. Since Xoma could begin reporting late stage […]
Continue at source –
Nasdaq 5,000: The cure or curse for biotech stocks
[…]
The Nasdaq Composite Index has nearly doubled since the end of 2011, led by its riskiest sector: biotechnology.But biotech companies vary more than most in other industries. Some have no hopes of ever making money. And others are backed by products that are established in the marketplace and are quite profitable.The Nasdaq Biotechnology Index NBI, +0.40% has risen 227% since […]
Stocks finished mixed again on Thursday in another quiet session. I checked the calendar, because the action feels eerily like a holiday reprieve. Where is everyone?Or maybe like a calm before a storm given threatening data on nascent deflation and a rollover in corporate earnings. I know it’s almost forbidden to say this out loud with sentiment so bubbly — […]
